Esperion to cut work force 40%

ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR), developers of a new class of cholesterol-lowering drugs, announced a 40 percent work force reduction and said it would focus its marketing efforts more …

New CEO at GR’s Tetra Therapeutics

GRAND RAPIDS—Officials at Tetra Therapeutics, a pharma startup developing drugs to treat brain disorders associated with cognitive and memory deficits, announced that CEO Mark Gurney had retired effective June 30. …

Esperion names chief medical officer

ANN ARBOR—Officials at the Ann Arbor cholesterol drug developer Esperion Therapeutics Inc. (Nasdaq: ESPR) announced the appointment of JoAnne Micale Foody, MD, FACC, FAHA as chief medical officer, effective immediately. …

Esperion names new president, CEO

ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) announced the appointment of Sheldon Koenig as president, CEO, and board member, effective immediately. He succeeds Tim Mayleben, whom company officials said “decided to …

Esperion secures $50M in financing

ANN ARBOR—Esperion Therapeutics (NASDAQ: ESPR), developers of a novel class of cholesterol-reducing drugs, announced that an investor group led by New York City-based Oberland Capital Management LLC agreed to provide …